BioSpace News Archive

Gene editing or genome editing is the targeted insertion or modification of cells in living organism or cells and the method has come to occupy a crucial part of biomedical researches, constantly transforming various disciplines of life sciences.

The market for coronary stents has been gaining significant traction across the world.

The demand within the global market for chronic myelogenous leukaemia treatment has been rising on account of advancements in the worldwide healthcare sector.

Transparency Market Research has published a new report titled, ‘Exocrine Pancreatic Insufficiency Therapeutics & Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Confo Therapeutics announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director.

Vizient, Inc. announced 12 additional drugs have been added to its essential medications list whose absence would threaten hospitals’ ability to provide high quality, timely patient care.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19.

The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 patients is being initiated in the U.S. TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a s

BiondVax Pharmaceuticals Ltd. announced the completion of the clinical study report of a Phase 2 clinical trial of the Company’s M-001 universal influenza vaccine candidate.

Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million Series C financing. Checkmate plans to use the proceeds from t